Skip to main content

Cancer and Metastasis Reviews

Ausgabe 1/2024

Defining and Understanding Cancer Cell Plasticity in Therapy Resistant

Inhalt (24 Artikel)

Preface

Hifzur R Siddique, Ajaikumar B Kunnumakkara

The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies

Sabrean Farhan Jawad, Farag M. A. Altalbawy, Radhwan M. Hussein, Ali Abdulhussain Fadhil, Mohammed Abed Jawad, Rahman S. Zabibah, Tasneem Younus Taraki, Chakrabhavi Dhananjaya Mohan, Kanchugarakoppal S. Rangappa

Open Access Review

Resveratrol as sensitizer in colorectal cancer plasticity

Aranka Brockmueller, Anjana Sajeev, Lenka Koklesova, Samson Mathews Samuel, Peter Kubatka, Dietrich Büsselberg, Ajaikumar B. Kunnumakkara, Mehdi Shakibaei

Open Access Review

Cell plasticity modulation by flavonoids in resistant breast carcinoma targeting the nuclear factor kappa B signaling

Peter Kubatka, Lenka Koklesova, Alena Mazurakova, Aranka Brockmueller, Dietrich Büsselberg, Martin Kello, Mehdi Shakibaei

Open Access REVIEW

B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention

Elizabeth Varghese, Samson Mathews Samuel, Aranka Brockmueller, Mehdi Shakibaei, Peter Kubatka, Dietrich Büsselberg

REVIEW

Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy

Vipin Singh, Sandhik Nandi, Aritra Ghosh, Santanu Adhikary, Shravanti Mukherjee, Siddhartha Roy, Chandrima Das

Open Access REVIEW

Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance

Gh Rasool Bhat, Itty Sethi, Hana Q. Sadida, Bilal Rah, Rashid Mir, Naseh Algehainy, Ibrahim Altedlawi Albalawi, Tariq Masoodi, Gowtham Kumar Subbaraj, Farrukh Jamal, Mayank Singh, Rakesh Kumar, Muzafar A. Macha, Shahab Uddin, Ammira S. Al-Shabeeb Akil, Mohammad Haris, Ajaz A. Bhat

REVIEW

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation

Milad Ashrafizadeh, Wei Zhang, Yu Tian, Gautam Sethi, Xianbin Zhang, Aiming Qiu

REVIEW

Targeting the key players of phenotypic plasticity in cancer cells by phytochemicals

Sajad Fakhri, Seyed Zachariah Moradi, Fatemeh Abbaszadeh, Farahnaz Faraji, Roshanak Amirian, Dona Sinha, Emily G. McMahon, Anupam Bishayee

REVIEW

Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?

Ravichandran Vishwa, Bandari BharathwajChetty, Sosmitha Girisa, Babu Santha Aswani, Mohammed S. Alqahtani, Mohamed Abbas, Mangala Hegde, Ajaikumar B. Kunnumakkara

REVIEW

Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics

Bandari BharathwajChetty, Anjana Sajeev, Ravichandran Vishwa, Babu Santha Aswani, Mohammed S. Alqahtani, Mohamed Abbas, Ajaikumar B. Kunnumakkara

REVIEW

Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance

Aliye Tabatabaee, Behjat Nafari, Armin Farhang, Amirali Hariri, Arezoo Khosravi, Ali Zarrabi, Mina Mirian

Open Access REVIEW

Clusterin: a marker and mediator of chemoresistance in colorectal cancer

Sara Hlavca, Wing Hei Chan, Rebekah M. Engel, Helen E. Abud

REVIEW

Deciphering cellular plasticity in pancreatic cancer for effective treatments

Md. Hafiz Uddin, Dingqiang Zhang, Irfana Muqbil, Bassel F. El-Rayes, Herbert Chen, Philip A. Philip, Asfar S. Azmi

REVIEW

From modulation of cellular plasticity to potentiation of therapeutic resistance: new and emerging roles of MYB transcription factors in human malignancies

Shashi Anand, Kunwar Somesh Vikramdeo, Sarabjeet Kour Sudan, Amod Sharma, Srijan Acharya, Mohammad Aslam Khan, Seema Singh, Ajay Pratap Singh

Open Access Review

Sam68 is a druggable vulnerability point in cancer stem cells

Amanda Mendes da Silva, Veronika Yevdokimova, Yannick D. Benoit

REVIEW

Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response

Nasim Ebrahimi, Mahdokht Sadat Manavi, Ferdos Faghihkhorasani, Siavash Seifollahy Fakhr, Fatemeh Jafari Baei, Fereshteh Faghih Khorasani, Mohammad Mehdi Zare, Nazanin Pazhouhesh Far, Fatemeh Rezaei-Tazangi, Jun Ren, Russel J. Reiter, Noushin Nabavi, Amir Reza Aref, Chu Chen, Yavuz Nuri Ertas, Qi Lu

Review

Glucocorticoid receptor: a harmonizer of cellular plasticity in breast cancer—directs the road towards therapy resistance, metastatic progression and recurrence

Debanjan Thakur, Debomita Sengupta, Elizabeth Mahapatra, Salini Das, Ruma Sarkar, Sutapa Mukherjee

Review

Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review

Sajad Fakhri, Seyed Zachariah Moradi, Farahnaz Faraji, Leila Kooshki, Kassidy Webber, Anupam Bishayee

Aktuelle Ausgaben

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.